In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Biogen, Sunesis in inflammatory and autoimmune disease pact

Executive Summary

In what it says is the largest corporate alliance in its four-year history, Sunesis Pharmaceuticals (compound Tethering fragment-based technology) is collaborating with biopharmaceutical genetic engineering company Biogen to develop oral drugs to treat inflammatory and autoimmune diseases.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • R+D and Marketing-Licensing
    • Intra-Biotech Deal
    • Includes Royalty or Profit Split Information

Related Companies

UsernamePublicRestriction

Register